MFFIA
BIIB icon

McIntyre, Freedman & Flynn Investment Advisers’s Biogen BIIB Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,089
Closed -$211K – 69
2024
Q3 		$211K Hold
1,089
– – 0.15% 62
2024
Q2 		$252K Hold
1,089
– – 0.18% 58
2024
Q1 		$235K Sell
1,089
-50
-4% -$11.7K 0.17% 58
2023
Q4 		$295K Hold
1,139
– – 0.24% 55
2023
Q3 		$293K Sell
1,139
-12
-1% -$3.21K 0.25% 54
2023
Q2 		$328K Hold
1,151
– – 0.28% 48
2023
Q1 		$320K Sell
1,151
-252
-18% -$69.7K 0.27% 50
2022
Q4 		$389K Buy
+1,403
New +$396K 0.32% 49

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's BIIB Position: Q4 2024 in Review

McIntyre, Freedman & Flynn Investment Advisers sold out of Biogen (BIIB) in Q4 2024, closing a stake of 1,089 shares — an estimated $211K sold.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in BIIB in Q4 2022 and held it in 8 quarters. The position peaked at $389K in Q4 2022. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

  • McIntyre, Freedman & Flynn Investment Advisers reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
  • McIntyre, Freedman & Flynn Investment Advisers sold 1,089 Biogen shares in Q4 2024, an estimated $211K.
  • McIntyre, Freedman & Flynn Investment Advisers first reported a position in Biogen in Q4 2022 and held it in 8 quarters.
  • McIntyre, Freedman & Flynn Investment Advisers's Biogen position peaked at $389K in Q4 2022.
  • 876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q4 2024, filed 7 Feb 2025.